Last updated: July 31, 2026
Trental is the former brand name for pentoxifylline extended-release tablets, an oral methylxanthine derivative approved for symptomatic treatment of intermittent claudication. Its commercial position is now mature and largely generic. No active patent barrier materially limits generic competition in the United States, and no late-stage clinical program has established a new approved indication. Future demand is likely to remain concentrated in low-cost generic use and selected off-label applications, including diabetic kidney disease, chronic kidney disease, peripheral vascular disease and inflammatory disorders.
What is Trental and what is pentoxifylline used for?
Trental contains pentoxifylline, a nonselective phosphodiesterase inhibitor that improves erythrocyte flexibility, reduces blood viscosity and may improve microcirculatory blood flow.
The FDA-approved indication is:
- Relief of symptoms associated with chronic occlusive arterial disease of the limbs, commonly called intermittent claudication.
- The drug improves walking distance and symptoms in some patients but does not reverse arterial obstruction.
- The usual extended-release dose is 400 mg three times daily with meals. Dose reduction may be required for adverse effects or renal impairment. [1]
Pentoxifylline is available primarily as generic extended-release 400 mg tablets. Brand availability varies by country. In the United States, Trental has little practical commercial significance compared with generic pentoxifylline.
What therapeutic areas use pentoxifylline off label?
Clinical researchers have evaluated pentoxifylline in several conditions:
| Area |
Evidence position |
Commercial relevance |
| Intermittent claudication |
Approved indication; modest symptomatic benefit |
Low, because inexpensive generics dominate |
| Diabetic nephropathy |
Small trials and meta-analyses suggest reductions in albuminuria and inflammatory markers |
Limited; not a broadly adopted standard therapy |
| Chronic kidney disease |
Investigational evidence, including combination use with renin-angiotensin system blockade |
Limited and not equivalent to regulatory approval |
| Nonalcoholic fatty liver disease and steatohepatitis |
Small clinical studies with inconsistent results |
Low |
| Radiation injury and fibrosis |
Experimental or off-label use |
Limited |
| Chronic venous disease and wound healing |
Mixed clinical evidence |
Niche |
| Severe inflammatory conditions |
Early or heterogeneous evidence |
No established market |
Pentoxifylline is not a disease-modifying replacement for antiplatelet therapy, statins, supervised exercise or revascularization in peripheral artery disease.
What is the current clinical-trial status of Trental?
Pentoxifylline has no major active Phase 3 development program comparable to a modern specialty pharmaceutical. Its clinical-trial activity is fragmented across investigator-sponsored studies, academic trials and repurposing programs.
What did the major peripheral artery disease trials show?
Evidence reviews have generally found that pentoxifylline produces a modest increase in pain-free or maximum walking distance in intermittent claudication. Results vary substantially by study design, baseline disease severity and comparator.
The drug has not displaced newer peripheral artery disease management strategies. Current treatment generally emphasizes:
- Smoking cessation
- Structured exercise therapy
- Statin treatment
- Antiplatelet therapy when indicated
- Blood-pressure and diabetes control
- Revascularization for selected patients with disabling symptoms
The Cochrane review of pentoxifylline for intermittent claudication found limited-to-moderate evidence of benefit, with inconsistent reporting and modest clinical effect. [2]
Is pentoxifylline being studied in diabetic kidney disease?
Yes. Pentoxifylline has been studied as an adjunct to standard renoprotective therapy, particularly in patients with type 2 diabetes and albuminuria.
The rationale is based on suppression of inflammatory signaling, including tumor necrosis factor-alpha, rather than a direct glucose-lowering mechanism. Studies have reported reductions in albuminuria and some inflammatory biomarkers. The main limitations are:
- Small sample sizes
- Heterogeneous endpoints
- Limited evidence for hard renal outcomes
- Lack of a regulatory approval for diabetic kidney disease
- Competition from SGLT2 inhibitors, GLP-1 receptor agonists and optimized renin-angiotensin system blockade
The VA NEPHRON-D and related renal-care evidence base has shifted treatment toward agents with demonstrated effects on kidney failure and cardiovascular outcomes. Pentoxifylline remains an adjunctive research or off-label option rather than a mainstream first-line therapy.
What is the evidence in chronic kidney disease?
The PREDIAN study evaluated pentoxifylline in patients with diabetic kidney disease receiving renin-angiotensin system blockade. The study reported slower decline in estimated glomerular filtration rate and reduced albuminuria compared with control over the study period. [3]
The findings generated continued academic interest, but they did not create a new commercial market. Larger outcome trials and guideline adoption would be necessary for a meaningful change in prescribing.
Is pentoxifylline being studied for COVID-19 or other inflammatory conditions?
Pentoxifylline has appeared in small repurposing studies involving inflammatory disease, acute lung injury and COVID-19-related inflammation. These programs have not produced a validated regulatory pathway or a durable commercial indication.
No evidence supports treating pentoxifylline as an established antiviral or standard COVID-19 therapy. Clinical use for these purposes remains investigational.
What is the FDA regulatory status of Trental?
Trental's active ingredient, pentoxifylline, was approved in the United States for intermittent claudication. The current U.S. market consists primarily of abbreviated new drug application products.
What is the Orange Book status of pentoxifylline?
Pentoxifylline extended-release tablets are generic prescription products listed in FDA drug databases. The original approval dates to the early generic-drug era, and the product has no commercially meaningful period of new-drug exclusivity remaining.
The key regulatory characteristics are:
| Regulatory factor |
Status |
| Active ingredient |
Pentoxifylline |
| Dosage form |
Extended-release oral tablet |
| Principal U.S. strength |
400 mg |
| Original indication |
Intermittent claudication |
| Current pathway |
Generic ANDA products |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
None relevant |
| Orphan exclusivity |
None relevant |
| Biosimilar pathway |
Not applicable |
| Orange Book patent barrier |
No material current barrier expected |
FDA product listings and labels should be checked for current manufacturer-specific status because generic approvals, discontinuations and marketing status can change over time. [1,4]
What patents protect Trental and pentoxifylline?
The original composition-of-matter and formulation protection for pentoxifylline expired long ago. Any patent rights that supported the original Trental launch are well beyond their statutory term.
Does pentoxifylline have active U.S. patent protection?
No commercially significant U.S. patent estate is generally associated with the original pentoxifylline molecule or the conventional 400 mg extended-release tablet.
Potential patent categories for an old generic product could include:
- Narrow modified-release formulations
- Manufacturing processes
- Particle-size or excipient systems
- New combinations
- Specific dosing regimens
- New methods of treatment
These categories do not create a meaningful barrier unless an enforceable patent is listed against a particular product or asserted in litigation. There is no established market narrative around a current Trental formulation patent blocking generic entry.
What are the global patent considerations?
Patent status varies by jurisdiction, but the original compound has been off patent internationally for decades. Generic penetration is therefore expected across Europe, Asia-Pacific and Latin America, subject to national registration requirements, local manufacturing rules and reimbursement controls.
The principal international barriers are regulatory and commercial rather than patent-based:
- Bioequivalence requirements for extended-release tablets
- Local pharmacopoeial standards
- Import and manufacturing approvals
- Tender eligibility
- Pricing regulation
- Supply-chain reliability
When did Trental lose exclusivity?
Trental lost meaningful exclusivity decades ago. The exact launch and patent chronology differs by country, but the product is now a mature generic medicine.
| Exclusivity type |
Current position |
| Compound patent |
Expired |
| Original formulation protection |
Expired or commercially irrelevant |
| FDA new-drug exclusivity |
Expired |
| Orphan exclusivity |
None |
| Pediatric exclusivity |
None |
| Market exclusivity |
Generic competition established |
| Current U.S. launch protection |
None of practical significance |
Are there Paragraph IV challenges to Trental?
Paragraph IV litigation is not a material current issue for pentoxifylline. The product's core patents are expired, and generic versions have been marketed for many years.
A Paragraph IV certification would matter only if a later-listed patent covered a specific product or method. For the conventional pentoxifylline extended-release tablet, the more relevant commercial question is generic manufacturing and distribution competition, not patent litigation.
What patent litigation affects Trental?
No major current U.S. patent litigation is associated with the core Trental product. Litigation risk could arise from a newly patented formulation or combination, but that would concern the later innovation rather than conventional pentoxifylline.
What is the market size for Trental and pentoxifylline?
Pentoxifylline is a low-value generic market. Public market reports often combine pentoxifylline with broader peripheral vascular disease, circulatory disorder or generic cardiovascular categories, producing estimates that are not directly comparable.
A defensible market assessment is:
- The U.S. brand market is minimal.
- Generic revenue is distributed among multiple manufacturers and wholesalers.
- Pricing is constrained by therapeutic substitution and low clinical differentiation.
- Demand is stable or declining in developed markets.
- Growth is more plausible in emerging markets where diagnosis and treatment of peripheral vascular disease are expanding.
- Off-label kidney and inflammatory uses have not generated a measurable branded premium.
What drives pentoxifylline revenue?
Revenue depends on prescription volume, generic pricing and geographic mix rather than innovation.
The main commercial drivers are:
- Prevalence of peripheral artery disease and intermittent claudication.
- Physician willingness to use pentoxifylline despite modest efficacy.
- Availability of lower-cost generic alternatives.
- Hospital and pharmacy formulary decisions.
- Use in countries where access to supervised exercise and revascularization is limited.
- Manufacturer participation in government tenders.
The main constraints are stronger guideline-supported therapies, low treatment persistence and frequent substitution with other vascular medicines.
What is the market forecast for Trental?
A precise global forecast is difficult because commercial databases classify pentoxifylline inconsistently. The most supportable projection is a mature-market scenario rather than a high-growth pharmaceutical forecast.
| Period |
Expected market direction |
Primary reason |
| 2024-2026 |
Flat to low-single-digit decline in developed markets |
Generic substitution and limited guideline momentum |
| 2026-2030 |
Stable niche demand globally |
Continued use in low-cost and emerging-market settings |
| 2030 onward |
Gradual erosion unless a new indication is validated |
Aging product and weak differentiation |
A major upside scenario would require positive, large-scale outcome data in diabetic kidney disease or another high-prevalence condition, followed by guideline adoption and regulatory expansion. Current evidence does not support assigning a high probability to that scenario.
How strong is the patent estate for Trental?
The patent estate is weak from an exclusivity perspective but strong in one narrow commercial sense: generic manufacturers face little risk of patent injunction against the conventional product.
| Estate attribute |
Assessment |
| Composition-of-matter protection |
Expired |
| Core formulation protection |
Expired or nonblocking |
| Method-of-use protection |
No material current barrier identified |
| Orange Book leverage |
Minimal |
| Paragraph IV exposure |
Low |
| Manufacturing barriers |
Moderate for reliable extended-release quality |
| Regulatory barriers |
Low to moderate |
| Pricing power |
Very low |
| Licensing value |
Low for the core product |
The extended-release dosage form still requires manufacturing control over dissolution and release characteristics. That creates quality and supply barriers, but not durable exclusivity.
Which companies compete with Trental?
Competition occurs at two levels.
Generic pentoxifylline manufacturers
Multiple regional and international manufacturers have marketed pentoxifylline tablets. The competitive set changes by country and may include large generic companies, specialty manufacturers and contract manufacturers.
Therapeutic alternatives
For intermittent claudication and peripheral artery disease, pentoxifylline competes with:
- Exercise therapy
- Cilostazol, where appropriate
- Antiplatelet drugs
- Statins
- Revascularization
- Risk-factor modification
Cilostazol has generally received stronger support for improving walking distance, although its contraindications and tolerability profile limit use in some patients. Pentoxifylline's low cost is its principal competitive advantage.
What generic launch scenarios exist for Trental?
Because generic entry is already established, future launch scenarios concern new suppliers or product extensions.
Base case
Generic manufacturers continue supplying 400 mg extended-release tablets. Prices remain low, and clinical use stays concentrated in legacy prescribing.
Downside case
Prescribing declines as clinicians prioritize exercise therapy, cilostazol, vascular intervention and newer cardiometabolic medicines. Manufacturers discontinue low-volume presentations, creating intermittent shortages without restoring pricing power.
Upside case
A well-controlled renal or inflammatory-disease program demonstrates clinically meaningful hard outcomes. The result supports guideline adoption, but the drug would still face generic pricing because new indication patents would need to be valid, enforceable and commercially useful.
What licensing deals involve Trental?
No major current licensing deal is central to the commercial strategy for conventional Trental or generic pentoxifylline. The molecule's age, generic status and low price reduce the likelihood of a significant branded licensing transaction.
Any value in a transaction would more likely involve:
- A new combination product
- A proprietary modified-release system
- A regional distribution agreement
- An investigator-generated indication
- A manufacturing or supply arrangement
These would be separate from the legacy Trental brand.
What is the commercial outlook for Trental?
Trental is a low-risk, low-return generic product. Its advantages are established clinical familiarity, broad manufacturing knowledge and low acquisition cost. Its weaknesses are weak differentiation, limited patent protection, modest efficacy and competition from better-supported treatment strategies.
For investors and licensing teams, the product has limited standalone value. The more relevant opportunity would be a validated repurposing program with a new clinical endpoint, proprietary delivery platform or combination regimen. Without that development, pentoxifylline is best viewed as a mature generic asset rather than a growth pharmaceutical.
Key Takeaways
- Trental is the legacy brand for pentoxifylline extended-release tablets.
- The FDA-approved use is symptomatic treatment of intermittent claudication.
- Clinical evidence shows modest benefit in walking performance, with variable results.
- Pentoxifylline has been studied in diabetic kidney disease and other inflammatory conditions, but no new indication has achieved broad regulatory or guideline adoption.
- Core composition and formulation patents have expired.
- No material current Paragraph IV or Orange Book litigation risk is associated with conventional pentoxifylline.
- Biosimilar risk does not apply because pentoxifylline is a small-molecule drug.
- The market is mature, generic and price-sensitive.
- Developed-market demand is likely flat to declining through 2030.
- Commercial upside depends on new clinical evidence, not the legacy Trental brand.
FAQs
Is Trental still approved in the United States?
Pentoxifylline remains available as an FDA-approved generic extended-release tablet for intermittent claudication. Brand availability under the Trental name is limited and may vary by market.
Can pentoxifylline replace cilostazol?
No. Pentoxifylline and cilostazol have different pharmacologic profiles, contraindications and evidence bases. Treatment selection depends on cardiovascular status, adverse-effect risk and physician assessment.
Does pentoxifylline have biosimilars?
No. Biosimilars apply to biologic medicines. Pentoxifylline is a conventional small-molecule drug and is supplied through generic drug approvals.
Is pentoxifylline useful for diabetic nephropathy?
Clinical studies suggest possible reductions in albuminuria and inflammatory markers, but pentoxifylline is not a primary approved treatment for diabetic nephropathy and has not displaced SGLT2 inhibitors or optimized renin-angiotensin system blockade.
Could a new pentoxifylline formulation obtain patent protection?
A new formulation, combination or treatment method could potentially receive patent protection if it satisfies patentability requirements. Such protection would not restore exclusivity to conventional Trental or existing generic pentoxifylline tablets.
References
-
U.S. Food and Drug Administration. (2019). Pentoxifylline extended-release tablets prescribing information. FDA.
-
Salhiyyah, K., Forster, R., Sayers, R. D., & D. J. (2015). Pentoxifylline for intermittent claudication. Cochrane Database of Systematic Reviews, 2015(9), CD005262.
-
Navarro-González, J. F., Mora-Fernández, C., Muros de Fuentes, M., et al. (2015). Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease. Journal of the American Society of Nephrology, 26(1), 220-229.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
